

Tata Medical Center

14 Major Arterial Road (EW)
Newtown, Rajarhat, Kolkata - 700 160
Tel.: + 91 33 66057000, Email : info@tmckolkata.com
www.tmckolkata.com



To,

Date: 21-Jul-2026

The Drugs Controller General (India)
Directorate General of Health Services.
FDA Bhawan, CHEB Campus
Kotla Road, New Delhi 110 002
India

Subject: Declaration of Number of Clinical Trials Undertaken by me as Principal Investigator

Study Title: Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

Study Code: D702NC00001


Dear Sir,

I would hereby like to declare that at present I am participating in 03 clinical trials as Principal Investigator. Details are listed below:

No. of ongoing studies 00	In Start-up Phase:03
	Recruiting:00
	Recruitment completed: 00

I have been adequately supported by sub-investigator(s) in the conduct of 03 clinical trials.

Your's truly,


21/07/2026
Dr. Prashant Pandey
Consultant Of Medical Oncology
Tata Medical Center
14 MAR(E-W), Newtown, Rajarhat
Kolkata-700160